Understand the source comparison
BPC-157 vs TB-500 vs CJC-1295: Mechanism Comparison
The table below directly compares the three peptides for frailty research most commonly evaluated in preclinical and clinical frailty studies. BPC-157 VEGF upregulation, angiogenesis Vascular endothelium, connective tissue Improved perfusion, accelerated tendo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below directly compares the three peptides for frailty research most commonly evaluated in preclinical and clinical frailty studies.
- BPC-157
- VEGF upregulation, angiogenesis
- Vascular endothelium, connective tissue
- Improved perfusion, accelerated tendon/ligament repair
- 10 mcg/kg subcutaneous daily
- Strong in rodent models, limited human data
- Best for injury-related mobility loss; weakest direct sarcopenia reversal
- Thymosin Beta-4
- Actin binding, satellite cell migration
- Skeletal muscle, immune tissue
- Faster muscle repair, reduced inflammation
- 6–10 mg/kg twice weekly
- Moderate in aged rodent models, minimal human frailty trials
- Best for chronic low-grade inflammation; mechanism distinct from anabolic peptides
- CJC-1295
- GHRH receptor agonist
- Anterior pituitary
- Sustained GH/IGF-1 elevation, increased lean mass
- 30–60 mcg/kg twice weekly
- Strong in younger subjects, variable in aged populations
- Best for subjects with intact GH reserve; limited benefit if pituitary function compromised
- The critical insight here: peptides for frailty research compared in head-to-head trials often measure the same endpoints (grip strength, gait speed, lean mass) but address entirely different rate-limiting steps in the frailty cascade. BPC-157 won't compensate for blunted GH secretion. CJC-1295 won't restore capillary density in ischemic tissue. TB-500 won't drive anabolic signalling without adequate protein intake. Researchers expecting one peptide to replicate another's results misunderstand the biology entirely.